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PN-Terminal Pro-B-Type Natriuretic Peptide, Vascular
Disease Risk, and Cholesterol Reduction Among
20,536 Patients in the MRC/BHF Heart Protection Study
Heart Protection Study Collaborative Group
Oxford, United Kingdom
Objectives We sought to assess the ability of N-terminal pro-B-type natriuretic peptide (N-BNP) to predict vascular events in
high-risk people and to test whether statins benefit people with high levels of N-BNP.
Background The predictive value of N-BNP for occlusive vascular events and the effects of statins in people with high N-BNP
levels are uncertain.
Methods A total of 20,536 people were assigned randomly to simvastatin 40 mg daily or placebo for an average of
5 years. Five baseline N-BNP groups were defined (386; 386 to 1,171; 1,172 to 2,617; 2,618 to 5,758; and
5,759 pg/ml).
Results Baseline N-BNP was strongly predictive of future vascular events independently of other characteristics. Com-
pared with participants with N-BNP 386 pg/ml, those with levels 5,759 pg/ml had adjusted relative risks for
major vascular events (MVEs) (i.e., major coronary events [MCE] [nonfatal myocardial infarction or coronary
death], stroke, or revascularization) of 2.26, for MCE of 3.09, for stroke of 1.80, and for heart failure (hospital-
ization or death) of 9.23 (all p  0.0001). Overall, simvastatin allocation reduced the relative risk of MVE by
24% (95% confidence interval 19 to 28). There was a trend toward smaller (but still significant) proportional re-
ductions in MVE among participants with greater baseline N-BNP levels, but the absolute benefits of simvastatin
allocation were similar at all N-BNP levels. Simvastatin allocation was also associated with a 14% (95% confi-
dence interval 0 to 25) proportional reduction in heart failure. No excess risk of other vascular and nonvascular
outcomes was observed with simvastatin allocation among participants with greater baseline values of N-BNP.
Conclusions In this study, N-BNP levels were strongly predictive not only of heart failure but also of MVEs. In people with high
N-BNP levels consistent with heart failure, statin allocation significantly reduced vascular risk, with no evidence
of hazard. (Heart Protection Study; http://www.controlledtrials.com/ISRCTN48489393/48489393) (J Am Coll
Cardiol 2007;49:311–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.052n
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arain-type natriuretic peptide (BNP), a hormone secreted in
he ventricular myocardium during periods of increased ven-
ricular stretch and wall-tension, plays an important role in the
egulation of blood pressure, blood volume, and sodium bal-
nce (1). Upon secretion, the BNP precursor is split into the
iologically active peptide and the more stable amino terminal
rohormone fragment (N-BNP or NT-proBNP). For several
ears, it has been known that N-terminal pro-B-type
rom the Heart Protection Study Collaborative Group, Clinical Trial Service Unit,
niversity of Oxford, Oxford, Oxfordshire, United Kingdom. Please see the Appen-
ix for a full list of members of the Heart Protection Study Collaborative Group
riting Committee. The MRC/BHF Heart Protection Study was funded by the
.K. Medical Research Council, the British Heart Foundation, Merck & Co., and
oche Vitamins Ltd. Both the Clinical Trial Service Unit and all members of the
riting Committee (see Appendix) have a policy of not accepting honoraria or other
ayments from the pharmaceutical industry, except for the reimbursement of costs to
articipate in scientific meetings.t
Manuscript received February 14, 2006; revised manuscript received August 22,
006, accepted August 28, 2006.atriuretic peptide (N-BNP) levels provide sensitive (and
easonably specific) tests for the diagnosis of heart failure
nd left ventricular dysfunction (2–5) and provide good
ndicators of disease severity and prognosis in patients with
eart failure (6). In addition, because N-BNP is released
fter cardiac ischemia, it also may provide a useful biomar-
er for the detection and prediction of vascular morbidity
nd mortality (7); a recent systematic review found N-BNP
o be a strong indicator of future cardiac events in patients
oth with and without symptomatic heart failure (8).
There is overwhelming evidence that lowering low-
ensity lipoprotein (LDL) cholesterol by using statins
educes vascular risk in a wide range of people (9). However,
t has been suggested that these benefits may not extend to
atients with or at high risk of developing heart failure
10,11), chiefly because low plasma lipid levels have been
ssociated with poorer prognosis among heart failure pa-
ients in observational studies (12,13). Consequently, hy-
s
u
r
o
t
s
w
a
L
f
M
D
M
P
a
R
1
r
K
s
a
m
a
f
h
s
o
h
v
d
S
i
a
f
p
e
a
p
o
d
p
t
a
M
b
t
a
c
r
s
d
n
i
p
a
W

F
i
(
a
u
d
s
r
a
f
e
n
(
c
p
v
n
a
r
t
d
D
f
S
d
e
a
b
1
p
w
m
M
312 Heart Protection Study Collaborative Group JACC Vol. 49, No. 3, 2007
N-BNP, Vascular Risk, and Cholesterol Lowering January 23, 2007:311–9potheses have been generated
concerning the possible impor-
tance in heart failure patients of
coenzyme Q10 levels (which are
reduced by statins), as well as the
possible beneficial effects that li-
poproteins may have through
binding and detoxifying endo-
toxins (11,14). Two large ran-
domized placebo-controlled tri-
als of rosuvastatin in patients
with heart failure, the CORONA
(Controlled rosuvastatin multi-
national study in heart failure)
study (15) and the GISSI
(Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto
miocardico acuto) heart failure
tudy (16), are now underway to help resolve these
ncertainties.
In this report, blood samples taken before entry into the
andomized placebo-controlled Heart Protection Study (17)
f statin therapy in 20,536 patients were used to assess: 1)
he relationships between N-BNP and the incidence of
ubsequent major vascular events and heart failure; 2)
hether the effects of statin treatment on vascular risk differ
ccording to N-BNP level; and 3) the effect of lowering
DL cholesterol with a statin on the incidence of heart
ailure.
ethods
etails of the objectives, design, and methods of the
edical Research Council/British Heart Foundation Heart
rotection Study have been reported previously (17,18), and
re summarized in this section.
ecruitment and eligibility criteria. Between 1994 and
997, 20,536 men and women ages 40 to 80 years at high
isk of vascular disease were recruited from 69 United
ingdom hospitals, assigned randomly to receive 40 mg of
imvastatin daily or matching placebo (and, separately, using
2-by-2 factorial design, to receive antioxidant vitamins or
atching placebo capsules) (19), and followed for an aver-
ge of 5 years. Ethics and regulatory approval was obtained
rom relevant authorities. To be eligible, patients had to
ave either a previous diagnosis of coronary disease, occlu-
ive disease of noncoronary arteries, or diabetes (type I or II)
r, for men ages 65 years or older, to have been treated for
ypertension. Subjects with heart failure were eligible pro-
ided that they were not breathless at rest, but heart failure
iagnoses were not recorded at baseline.
creening, run-in phase, and randomization. At the
nitial screening visit, nurses completed a brief questionnaire
bout the patient’s past medical history and other relevant
actors; measured the person’s height, weight, and blood
Abbreviations
and Acronyms
BNP  brain-type
natriuretic peptide
CI  confidence interval
LDL  low-density
lipoprotein
LVEF  left ventricular
ejection fraction
MCE  major coronary
event
MI  myocardial infarction
MVE  major vascular
event
N-BNP  N-terminal pro-B-
type natriuretic peptideressure; and took a nonfasting blood sample. Potentially gligible patients were given information about the study and
sked for their written agreement to participate. Consenting
articipants entered a “run-in” phase, consisting of 4 weeks
f placebo followed by 4 to 6 weeks of 40 mg of simvastatin
aily. Compliant individuals who did not have a major
roblem during the run-in and who were not withdrawn by
heir family doctor were assigned randomly into the study
nd had their current medication recorded.
easurement of blood lipids and N-BNP. Screening
lood samples were cooled and sent by overnight courier to
he coordinating central laboratory for immediate separation
nd assay and for long-term storage. Lipid fractions (in-
luding LDL measured directly) were analyzed as previously
eported (18). The assay of N-BNP in stored plasma
amples was based on the noncompetitive N-BNP assay
escribed by Karl et al. (20). After an average of 4.6 years,
onfasting blood was collected from all participants attend-
ng final follow-up. A random sample of 1,174 of these
articipants (approximately 5%) was selected, and baseline
nd final follow-up N-BNP levels were remeasured.
ithin- and between-assay coefficients of variation were
5% for measurements of blood lipids and N-BNP.
ollow-up of vascular events. Participants were to be seen
n the study clinics at regular periods throughout follow-up
with nonattending patients followed by telephone or,
lternatively, through their family doctor). At each follow-
p, information was recorded about any suspected myocar-
ial infarction (MI), stroke, vascular procedure, or other
erious adverse experience (including hospitalization for any
eason). Further details were sought from family doctors
bout all reports (including admissions to hospital for heart
ailure or breathlessness) that might relate to major vascular
vents, cancers or deaths, and from United Kingdom
ational registries about certified causes of death. Outcomes
including heart failure) were coded by the coordinating
enter clinical staff in a blinded fashion (17). The primary
respecified end point for subgroup analyses was “major
ascular events” (MVE), which was defined as major coro-
ary events (MCE) (i.e., coronary death and nonfatal MI),
ny stroke (fatal or nonfatal), or coronary or noncoronary
evascularization. Heart failure was defined as hospitaliza-
ion for heart failure and death from heart failure (including
eaths for which the underlying cause was coronary).
uring the study, 20,469 participants (99.7%) had complete
ollow-up for both mortality and morbidity.
tatistical analysis. Five baseline N-BNP groups were
efined such that similar numbers of MVEs occurred in
ach group, which ensured similar sized confidence intervals
round risk estimates for this end point. These 5 groups had
aseline N-BNP measurements of 386; 386 to 1,171;
,172 to 2,617; 2,618 to 5,758; and 5,759 pg/ml. The few
atients with missing N-BNP at baseline (n  137; 0.7%)
ere allocated to the middle group (findings were not
aterially altered by their exclusion). Relative hazards of
VE, MCE, stroke, and heart failure for each N-BNProup compared with the lowest group were estimated using
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January 23, 2007:311–9 N-BNP, Vascular Risk, and Cholesterol Loweringox proportional hazards regression and presented as “float-
ng absolute risks” (21), which allow an appropriate variance
o be ascribed to each group (including the reference group).
nalyses were performed before and after adjustment for
aseline age, gender, prior diseases, drug use, randomization
o simvastatin, apolipoprotein A1, apolipoprotein B, systolic
lood pressure, cigarette smoking status, body mass index,
nd estimated glomerular filtration rate using the Modifi-
ation of Diet in Renal Disease formula (22). Chi-square
ests for linear trend in the relative risk with increasing log
-BNP level were performed.
Analyses of the effect of randomization to simvastatin on
isk of first MVE, MCE, and stroke were performed both
verall and separately within each N-BNP group using
og-rank analyses. Chi-square tests for linear trend in the
ffect of simvastatin with increasing log N-BNP level were
erformed. Log-rank analyses were used to estimate the
ffect of randomization to simvastatin on the overall risk of
eart failure but not separately in each N-BNP group (as a
esult of the relatively small number of such events). This
nalysis was repeated after censoring of patients who, in the
bsence of heart failure, had a nonfatal MI (to examine the
ossibility that any apparent effect on heart failure may be
econdary to effects on MI). In the 1,174 participants with
epeat N-BNP samples, comparisons of the average change
n log N-BNP between the simvastatin and placebo groups
ere performed using the Student’s t test. All statistical tests
ere 2-sided and performed on an intention-to-treat basis.
esults
-BNP and cardiovascular risk factors at baseline. Base-
ine N-BNP levels were substantially skewed (skewness coef-
cient of 2.7), with a median of 1,091 pg/ml and an interquar-
ile range of 330 to 3,028 pg/ml. The baseline characteristics of
tudy participants in the five N-BNP-defined groups are
hown in Table 1. Patients with greater N-BNP levels at
aseline were older, more likely to have existing coronary
isease, and more likely to be taking cardioprotective drugs
han subjects with lower baseline N-BNP levels. Patients with
reater baseline N-BNP levels also had slightly lower mean
lood pressure, which was independent of reported blood
ressure-lowering drug use. In contrast, proportions of men,
ean blood lipid levels, and cigarette smoking rates varied little
y N-BNP level, whereas subjects with high N-BNP levels
ere slightly leaner than those with low N-BNP. Mean
lomerular filtration rate also decreased steadily with increasing
aseline N-BNP level. Perhaps as a consequence of the
nclusion criteria for the trial (virtually all subjects had either
rior vascular disease or diabetes), diabetes in this population
as more commonly observed among subjects with lower
-BNP levels.
-BNP and the incidence of MVE, MCE, stroke, and
eart failure. The 5-year floating absolute risks of MVE,
CE, stroke, and heart failure by baseline N-BNP groupre shown in Table 2, both before and after adjustment for Tther baseline risk factors (also see Fig. 1). The risks of
VE, MCE, stroke and, particularly, heart failure in-
reased progressively with increasing N-BNP. Compared
ith individuals with N-BNP levels 386 pg/ml, the
nadjusted relative risk for subjects with baseline N-BNP
evels 5,759 pg/ml was 2.78 for MVE, 4.70 for MCE,
.47 for stroke, and 16.0 for heart failure (all p  0.0001).
aking into account the differences in baseline characteris-
ics had a marked effect on these estimates, with the relative
isks being reduced to 2.26 for MVE, 3.09 for MCE, 1.80
or stroke, and 9.23 for heart failure (but all were still p 
.0001). Among individuals with N-BNP 386 pg/ml,
urther subdivision (40; 40, 100; and 100, 386
g/ml) did not demonstrate substantial differences in annual
vent rates: 3.3%, 3.4%, and 3.5% for MVE; 1.1%, 1.2%,
nd 1.3% for MCE; 0.7%, 0.9%, and 0.8% for stroke; and
.1%, 0.1%, and 0.2% for heart failure, respectively.
imvastatin allocation and risk of MVE, MCE, and
troke by N-BNP level. The randomization of large num-
ers of people in the study produced good balance in baseline
haracteristics between the treatment groups both overall (17)
nd separately in each baseline N-BNP group (including for
he use of concomitant medications). Compared with alloca-
ion to placebo, allocation to simvastatin reduced LDL cho-
esterol by an average of 1 mmol/l during the 5-year treatment
eriod. The effect of simvastatin allocation on the incidence of
VE, MCE, and stroke by baseline N-BNP level is shown in
igure 2. Overall, as previously reported (17), the relative risk
fMVEwas reduced by 24% (95% confidence interval [CI] 19
o 28). There was a significant trend (p 0.03) toward smaller,
lthough still highly statistically significant, proportional re-
uctions in MVE risk with simvastatin among participants
ho had greater baseline N-BNP levels (despite similar abso-
ute LDL cholesterol reductions in each N-BNP group: data
ot shown). However, because people with greater baseline
-BNP levels had a greater absolute risk ofMVE, the absolute
enefits of simvastatin were similar at all levels of N-BNP (Fig.
). Overall, allocation to simvastatin reduced the relative risk of
CE by 27% (95% CI 21 to 33) and the relative risk of stroke
y 25% (95% CI 15 to 34). The trend in the proportional
eduction in MVE risk by N-BNP level reflected a highly
ignificant trend for MCE (p  0.0001), with no clear trend
or stroke (p  0.23). The proportional reductions in vascular
eath (overall risk reduction 17%; 95% CI 9 to 25) and
onvascular death (overall risk reduction 5%; 95% CI 7 to
5) were not significantly different across the different N-BNP
roups (Fig. 4). In particular, there was no suggestion of any
dverse effect of statin therapy among patients with greater
-BNP levels.
imvastatin allocation, heart failure, and follow-up
-BNP. Randomization to simvastatin was associated
ith a marginally significant 14% (95% CI 0 to 25)
roportional reduction in the risk of hospitalization or death
ue to heart failure (348 [3.4%] simvastatin vs. 402 [3.9%]
lacebo; p  0.05) during the scheduled treatment period.
his estimate was unaffected when patients who had a
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N-BNP, Vascular Risk, and Cholesterol Lowering January 23, 2007:311–9onfatal MI before any heart failure event being observed
ere censored at the time of their MI. Levels of N-BNP
ere remeasured in blood collected after an average of 4.6
ears from a random sample of 1,174 participants. On
verage, follow-up N-BNP levels were 1.49 (95% CI 1.42 to
.57) times higher than baseline levels. However, this
elative increase in N-BNP level during the study differed
ignificantly (p  0.001) according to treatment allocation:
.37 (95% CI 1.28 to 1.47) for patients allocated to
imvastatin versus 1.64 (95% CI 1.52 to 1.76) for patients
llocated to placebo. Exclusion of 341 patients who had a
ajor vascular event, other vascular event, or admission to
ospital for heart failure or angina in the period between the
aseline and follow-up N-BNP samples did not explain this
ifference: after such exclusions, the mean proportional
aseline Characteristics by Baseline N-BNP Level
Table 1 Baseline Characteristics by Baseline N-BNP Level
<386
Subjects, n 5,658
Mean (SD) N-BNP, pg/ml 141 (122)
Mean (SD) age at randomization, yrs 59.0 (8.5)
Men, % 75.9
Mean (SD) blood lipids*
Apolipoprotein A1, g/l 1.21 (0.22)
Apolipoprotein B, g/l 1.15 (0.24)
High-density lipoprotein cholesterol, mmol/l 1.05 (0.33)
Low-density lipoprotein cholesterol, mmol/l 3.40 (0.87)
Mean (SD) blood pressure, mm Hg*
Systolic 145.5 (24.3)
Diastolic 82.9 (12.8)
Mean (SD) estimated glomerular filtration rate, ml/min* 77.63 (15.73)
Cigarette smoking status, %*
Current smokers 14.8
Ex-smokers 59.9
Body mass index, kg/m2*
Mean (SD) 28.0 (4.6)
Obese (30), % 27.5
Overweight (25), % 76.0
Prior coronary heart disease, %*
Myocardial infarction 22.2
Other CHD without MI 23.1
None 53.9
Other prior disease, %*
Cerebrovascular disease 16.9
Peripheral vascular disease 34.4
Other coronary disease 39.3
Diabetes 40.5
Drug use, %*
ACE inhibitors 15.6
Beta-blockers 10.6
Diuretics 17.2
Any treatment for hypertension 35.4
Aspirin 52.2
Lipid-lowering drug 0.4
ategories are defined such that an approximately equal number of subsequent major vascular e
ACE  angiotensin-converting enzyme; CHD  coronary heart disease; MI  myocardial infarctncreases in N-BNP levels were 1.28 (95% CI 1.19 to 1.38) hith simvastatin and 1.46 (95% CI 1.36 to 1.58) with
lacebo (p  0.01). (Randomization to receive vitamins in
he Heart Protection Study was associated with a 20% [95%
I 4 to 38] increase in hospitalization or death due to heart
ailure [408 (4.0%) vitamins vs. 342 (3.4%) placebo; p 
.01]. Among those with repeat N-BNP measurements, the
ean proportional increases in N-BNP level during the
tudy were 1.57 [95% CI 1.46 to 1.68] with vitamins and
.42 [95% CI 1.32 to 1.52] with placebo [p  0.04]).
iscussion
-BNP is a strong indicator of future vascular event
isk. This study of more than 20,000 people at high risk of
ascular disease, including patients with mild-to-moderate
N-BNP Level (pg/ml)
386–1,171 1,172–2,617 2,618–5,758 >5,759
4,862 4,209 3,371 2,436
732 (224) 1,802 (417) 3,907 (890) 10,349 (4,295)
63.2 (8.1) 65.6 (7.3) 67.5 (6.7) 69.2 (6.1)
74.1 74.4 75.3 77.2
1.21 (0.21) 1.20 (0.21) 1.19 (0.21) 1.18 (0.21)
1.14 (0.23) 1.14 (0.23) 1.14 (0.24) 1.13 (0.24)
1.07 (0.31) 1.05 (0.31) 1.05 (0.32) 1.06 (0.32)
3.38 (0.82) 3.36 (0.82) 3.37 (0.83) 3.35 (0.84)
44.3 (23.0) 144.0 (23.1) 144.2 (23.4) 142.4 (23.7)
81.4 (12.1) 80.6 (12.2) 80.5 (12.3) 80.4 (12.5)
4.92 (14.91) 72.78 (14.96) 70.80 (15.14) 65.58 (15.31)
15.4 13.3 12.7 13.5
60.2 61.6 61.4 59.8
27.5 (4.3) 27.5 (4.4) 27.4 (4.4) 27.1 (4.5)
23.9 23.3 22.8 20.1
71.9 72.3 70.1 66.0
35.1 45.5 54.6 60.9
26.0 25.0 22.4 19.6
37.7 28.2 21.8 18.3
14.9 15.0 15.1 19.1
32.2 32.2 32.4 33.3
52.7 60.3 65.7 66.8
29.4 24.9 21.5 21.0
15.1 17.9 20.2 33.6
20.5 30.1 37.0 33.9
20.1 22.2 26.4 43.0
37.3 43.3 45.5 49.1
62.6 68.7 69.4 67.7
0.3 0.2 0.2 0.4
ccurs in each group. *Adjusted for age and gender.
NP  N-terminal pro-B-type natriuretic peptide.1
7eart failure, provides reliable evidence that N-BNP is
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January 23, 2007:311–9 N-BNP, Vascular Risk, and Cholesterol Loweringtrongly and positively related not only to subsequent
ospitalization or death due to heart failure but also to
ajor occlusive vascular events in such patients. When
ompared with individuals who had baseline measurements
f N-BNP level 386 pg/ml (28% of the study population
ut, by design, 20% of MVE events), individuals with
aseline N-BNP measurements 5,759 pg/ml (12% of the
opulation but 20% of MVE events) had more than twice
he risk of MVE and more than 3 times the risk of MCE,
ven after accounting for differences in other baseline
haracteristics (Table 2).
Previous studies of the prognostic strength of N-BNP for
cclusive vascular events typically have been based on
atients with acute coronary syndromes (23–25). In one
tudy of 6,809 patients with non–ST-segment elevation
cute coronary syndrome, the risk of MI over the following
0 days increased with increasing quartile of N-BNP, from
.7% in the lowest quartile to 7.5% in the highest quartile
25). Similar observations also have been made in non-
ospitalized individuals (26–28). For example, in the Fra-
ingham Heart Study, a 1-SD increase in log BNP was
ssociated with a 28% increase in the risk of a first
ardiovascular event (which is consistent with the respective
stimate in the Heart Protection Study; see footnote to Fig.
) and a 53% increase in the risk of stroke or transient
schemic attack (26). A recent population-based study in
enmark found that the 5-year incidence of major cardio-
ascular events increased by 92% for each SD increase in log
-BNP, whereas ischemic stroke risk increased by 76%
27). However, these values should be interpreted with
isk of Major Vascular Events, Stroke, Major Coronary Events, andospitaliz tion or De th, by Baseline N-BNP Level
Table 2 Risk of Major Vascular Events, Stroke, Major CoronaryHospitalization or Death, by Baseline N-BNP Level
<386 386–1,171
Subjects, n 5,658 4,862
Major vascular event
Number of events (%) 919 (16.2%) 913 (18.8%)
Unadjusted HR (95% CI) 1.00 (0.94–1.07) 1.17 (1.10–1.25)
Fully adjusted HR (95% CI)† 1.00 (0.93–1.08) 1.13 (1.06–1.21)
Major coronary event
Number of events (%) 345 (6.1%) 356 (7.3%)
Unadjusted HR (95% CI) 1.00 (0.90–1.11) 1.20 (1.08–1.34)
Fully adjusted HR (95% CI)† 1.00 (0.89–1.13) 1.10 (0.99–1.22)
Stroke
Number of events (%) 215 (3.8%) 183 (3.8%)
Unadjusted HR (95% CI) 1.00 (0.87–1.14) 1.00 (0.86–1.15)
Fully adjusted HR (95% CI)† 1.00 (0.86–1.17) 0.89 (0.77–1.03)
Heart failure
Number of events (%) 58 (1.0%) 83 (1.7%)
Unadjusted HR (95% CI) 1.00 (0.77–1.29) 1.67 (1.35–2.07)
Fully adjusted HR (95% CI)† 1.00 (0.76–1.32) 1.49 (1.20–1.87)
Test of linear trend between log(N-BNP) concentration and risk; †adjusted for age, gender, prior vas
isease, diabetes, and all 2-, 3-, 4- and 5-way interactions between these disease categories), base
igarette smoking status, body mass index, and estimated glomerular filtration rate.
CI  confidence interval; HR  hazard ratio; N-BNP  N-terminal pro-B-type natriuretic peptideaution because the relationships do not seem to be straight iines (i.e., the relative risk associated with a given difference
n baseline log N-BNP is not the same at all levels of log
-BNP) (see Fig. 1). Moreover, the strength of the rela-
ionship between long-term “usual” log N-BNP levels and
isk is likely to be underestimated by analyses based on
ingle “baseline” N-BNP measurements because of regres-
ion dilution bias (29). A recent review of 24 studies that
sed BNP or N-BNP to estimate relative risks for death,
ardiac death, sudden death, or cardiovascular events con-
luded that N-BNP was a strong prognostic indicator of
hese outcomes in populations both with and without heart
ailure (8). Our findings support this conclusion, providing
lear evidence that N-BNP is a powerful marker of vascular
vents in a wide range of people at high vascular event risk.
owering LDL cholesterol reduces vascular risk irrespec-
ive of N-BNP level. The present results show that low-
ring LDL cholesterol by 1 mmol/l with a statin reduces the
isk of vascular events at all levels of baseline N-BNP
tudied, including among individuals with high levels con-
istent with a diagnosis of heart failure. Although the
roportional reduction in MVE risk appeared to be smaller
or patients with the highest baseline N-BNP levels (Fig. 2),
he absolute numbers of MVEs avoided per 1,000 patients
reated was similar across baseline N-BNP categories be-
ause of the higher absolute risks among people with higher
-BNP levels (Fig. 3).
The hypothesis that cholesterol reduction could cause
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resence of heart failure, lipoproteins may provide protec-
ion through the binding and detoxifying of endotoxins
14). This hypothesis has helped perpetuate a belief that
atients with or at high risk of developing heart failure (even
hose with pre-existing coronary disease) should not be
reated with statins until the results from clinical trials of
atients with heart failure are known (10,11). However,
revious cholesterol-lowering trials have failed to provide
ny evidence in favor of this position: indeed, if anything,
hey have suggested the opposite. Secondary analysis of a
rial in MI survivors with average cholesterol levels found
hat pravastatin was equally effective among those who
resented with left ventricular ejection fraction (LVEF)
etween 25% and 40% as in those with LVEF 40%
Figure 1 Relative Hazard of Vascular Events and Hospitalizatio
by Baseline N-BNP Level (Adjusted for Differences in B
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eath due to heart failure. Although this reduction remains
tatistically consistent with there being little or no reduction
n risk, it does not provide support for concerns that
owering LDL cholesterol might materially increase the risk
Figure 2 Effects of Simvastatin on Vascular Events in Participa
CI  confidence interval; N-BNP  N-terminal pro-B-type natriuretic peptide.
Figure 3 Absolute Benefits of Simvastatin Allocation on
First MVE and First MCE, by Baseline N-BNP Level
Absolute benefits of simvastatin allocation on first major vascular event (MVE)
and first major coronary event (MCE) in participants subdivided by baseline
N-terminal pro-B-type natriuretic peptide (N-BNP) level. P  placebo; S 
simvastatin.cf heart failure. Moreover, the mean increase in N-BNP
evels during the study was lower among those allocated to
imvastatin than among those allocated placebo. It is pos-
ible that these findings reflect a reduced incidence of
ascular events (which may not have been fully taken into
ccount in our analyses), rather than direct effects of statin
herapy on heart function. In a previous randomized trial of
ypercholesterolemic patients with coronary heart disease
ut without evidence of congestive heart failure, simvastatin
roduced a significant 20% proportionally lower risk of
eveloping heart failure during the following 5 years (32),
hereas in another secondary prevention trial atorvastatin
roduced a significant 50% reduction in the development of
ew heart failure (31). Other large statin trials generally
ave failed to show significant effects of cholesterol reduc-
ion on heart failure risk, but the confidence intervals have
een wide because of low event rates or early termination
fter the emergence of clear benefit on the primary end
oint of occlusive vascular events (33).
tudy limitations. Because the presence of heart failure
as not recorded at baseline in HPS, it was not possible to
stimate directly the effect of simvastatin in patients with
nd without heart failure at randomization. Instead,
-BNP was used as a surrogate measure for baseline
vidence of heart failure because it is well established that it
rovides a highly sensitive indicator of existing heart failure
2), as well as a powerful indicator for future risk of heart
ailure (as is also suggested in the present study). No
djustment was made for multiple comparisons, and the
pparent trend toward smaller relative reductions in major
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lay of chance. Another potential limitation was that
ospitalization or death due to heart failure was not pre-
pecified as an end point. However, further information was
ought systematically about all reports of possible heart
ailure to ensure that prespecified outcomes (such as MI)
ere not missed. Hence, reports of hospitalization or death
ue to heart failure were confirmed centrally in most cases
ased on blind review of medical records. Finally, it is
ossible that because this study comprises people selected to
articipate in a randomized controlled trial, the observa-
ional relationships between baseline N-BNP and risk may
ot necessarily be generalizable to other populations. Nev-
rtheless, they should be widely generalizable to the types of
igh-risk patients studied.
onclusions. In people at high risk of vascular disease,
-BNP is strongly related to the subsequent incidence of
VE, major coronary event, and stroke, as well as being
ighly predictive of the risk of hospitalization or death due
o heart failure. Reducing LDL cholesterol by 1 mmol/l
ith statin therapy produced highly significant reductions in
he risk of MVEs, even in people with greater N-BNP levels
onsistent with a diagnosis of heart failure, without evidence
f hazard. Because the use of 40 mg of simvastatin typically
educes LDL cholesterol by 1.5 mmol/l, full compliance
ay result in even greater benefits among these high-risk
atients.
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